Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice.

Antineoplastic Cancer treatment Clock genes Cortex Corticosterone Free-running Hippocampus Master clock Suprachiasmatic nucleus (SCN)

Journal

Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478

Informations de publication

Date de publication:
01 2022
Historique:
received: 28 06 2021
revised: 07 09 2021
accepted: 18 09 2021
pubmed: 27 9 2021
medline: 15 3 2022
entrez: 26 9 2021
Statut: ppublish

Résumé

Cancer patients experience circadian rhythm disruptions in activity cycles and cortisol release that correlate with poor quality of life and decreased long-term survival rates. However, the extent to which chemotherapy contributes to altered circadian rhythms is poorly understood. In the present study, we examined the extent to which paclitaxel, a common chemotherapy drug, altered entrained and free-running circadian rhythms in wheel running behavior, circulating corticosterone, and circadian clock gene expression in the brain and adrenal glands of tumor-free mice. Paclitaxel injections delayed voluntary wheel running activity onset in a light-dark cycle (LD) and lengthened the free-running period of locomotion in constant darkness (DD), indicating an effect on inherent suprachiasmatic nucleus (SCN) pacemaker activity. Paclitaxel attenuated clock gene rhythms in multiple brain regions in LD and DD. Furthermore, paclitaxel disrupted circulating corticosterone rhythms in DD by elevating its levels across a 24-hour cycle, which correlated with blunted amplitudes of Arntl, Nr1d1, Per1, and Star rhythms in the adrenal glands. Paclitaxel also shortened SCN slice rhythms, increased the amplitude of adrenal gland oscillations in PER2::luciferase cultures, and increased the concentration of pro-inflammatory cytokines and chemokines released from the SCN. These findings indicate that paclitaxel disrupts clock genes and behavior driven by the SCN, other brain regions, and adrenal glands, which were associated with chemotherapy-induced inflammation. Together, this preclinical work demonstrates that chemotherapy disrupts both central and peripheral circadian rhythms and supports the possibility that targeted circadian realignment therapies may be a novel and non-invasive way to improve patient outcomes after chemotherapy.

Identifiants

pubmed: 34563619
pii: S0889-1591(21)00555-9
doi: 10.1016/j.bbi.2021.09.011
pmc: PMC8671246
mid: NIHMS1745379
pii:
doi:

Substances chimiques

Period Circadian Proteins 0
Paclitaxel P88XT4IS4D

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-118

Subventions

Organisme : NIA NIH HHS
ID : R01 AG065830
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216290
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM133032
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Brain Behav Immun. 2019 Aug;80:805-817
pubmed: 31108169
Biol Res Nurs. 2016 Jul;18(4):370-85
pubmed: 26957308
Brain Behav Immun. 2013 Mar;30 Suppl:S109-16
pubmed: 22698992
Breast Cancer Res Treat. 2016 Jul;158(1):43-50
pubmed: 27314577
Hippocampus. 2010 Mar;20(3):377-88
pubmed: 19437502
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5
pubmed: 6103535
Brain Behav Immun. 2016 Feb;52:98-105
pubmed: 26456694
Br J Cancer. 1996 Oct;74(8):1248-52
pubmed: 8883412
Psychoneuroendocrinology. 2017 Oct;84:139-142
pubmed: 28711723
Annu Rev Physiol. 2010;72:517-49
pubmed: 20148687
Brain Res. 2017 Sep 15;1671:93-101
pubmed: 28709906
Eur J Neurosci. 2016 Nov;44(10):2795-2806
pubmed: 27562056
Psychoneuroendocrinology. 2004 Sep;29(8):1082-92
pubmed: 15219660
Cell. 2002 Jul 26;110(2):251-60
pubmed: 12150932
J Biol Rhythms. 2006 Oct;21(5):350-61
pubmed: 16998155
Cell. 2000 Dec 22;103(7):1009-17
pubmed: 11163178
Chronobiol Int. 2002 Jan;19(1):43-55
pubmed: 11962685
Sci Rep. 2019 Nov 11;9(1):16490
pubmed: 31712703
Cell. 1999 Jul 23;98(2):193-205
pubmed: 10428031
J Clin Oncol. 2012 Oct 20;30(30):3675-86
pubmed: 23008308
Biochem Biophys Res Commun. 2018 Jun 22;501(2):593-597
pubmed: 29753739
Brain Behav Immun. 2014 May;38:66-76
pubmed: 24412646
Chronobiol Int. 2011 May;28(5):458-70
pubmed: 21721861
Annu Rev Pharmacol Toxicol. 2010;50:377-421
pubmed: 20055686
Chronobiol Int. 2017;34(5):609-623
pubmed: 28276853
Behav Brain Res. 2016 Jul 15;308:222-35
pubmed: 27091299
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12843-8
pubmed: 17646651
Ann Oncol. 2015 Jul;26(7):1446-51
pubmed: 25922060
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Sleep Med. 2019 Mar;55:14-21
pubmed: 30743205
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16219-24
pubmed: 25349387
Biochem Pharmacol. 2008 Apr 15;75(8):1616-22
pubmed: 18329632
J Endocrinol. 1979 Oct;83(1):1-16
pubmed: 230270
Bioinformatics. 2016 Nov 1;32(21):3351-3353
pubmed: 27378304
Comp Med. 2011 Apr;61(2):119-30
pubmed: 21535922
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20970-5
pubmed: 19091946
Cell. 1999 Jan 8;96(1):57-68
pubmed: 9989497
Eur J Neurosci. 2001 Mar;13(6):1190-6
pubmed: 11285016
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5339-46
pubmed: 14963227
Science. 1998 Jun 5;280(5369):1564-9
pubmed: 9616112
Nat Struct Mol Biol. 2005 May;12(5):441-8
pubmed: 15821743
J Biol Rhythms. 2007 Apr;22(2):159-66
pubmed: 17440217
Sci Rep. 2016 Oct 31;6:36035
pubmed: 27796320
Cell. 1997 Dec 26;91(7):1055-64
pubmed: 9428527
Psychoneuroendocrinology. 2017 Sep;83:25-41
pubmed: 28578301
Genome Biol. 2007;8(11):R247
pubmed: 18028544
Cereb Cortex. 2018 Feb 1;28(2):644-657
pubmed: 28052921
Sleep. 2009 Sep;32(9):1155-60
pubmed: 19750920
Curr Biol. 2008 Feb 26;18(4):286-91
pubmed: 18291650
Clin Cancer Res. 2000 Aug;6(8):3038-45
pubmed: 10955782
Behav Brain Res. 2021 Feb 5;399:113041
pubmed: 33279635
J Biol Rhythms. 2015 Oct;30(5):417-36
pubmed: 26271538
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11336-11341
pubmed: 27655894
Cell Metab. 2006 Aug;4(2):163-73
pubmed: 16890544
Sleep. 2017 Jun 1;40(6):
pubmed: 28444394
J Natl Cancer Inst. 2000 Jun 21;92(12):994-1000
pubmed: 10861311
Science. 2000 Sep 29;289(5488):2344-7
pubmed: 11009419

Auteurs

Kyle A Sullivan (KA)

Institute for Behavioral Medicine Research, Ohio State University, Columbus, OH, USA; Department of Neuroscience, Ohio State University, Columbus, OH, USA; James Comprehensive Cancer Center and Solove Research Institute, Ohio State University, Columbus, OH, USA.

Corena V Grant (CV)

Institute for Behavioral Medicine Research, Ohio State University, Columbus, OH, USA; James Comprehensive Cancer Center and Solove Research Institute, Ohio State University, Columbus, OH, USA.

Kelley R Jordan (KR)

Institute for Behavioral Medicine Research, Ohio State University, Columbus, OH, USA.

Karl Obrietan (K)

Department of Neuroscience, Ohio State University, Columbus, OH, USA.

Leah M Pyter (LM)

Institute for Behavioral Medicine Research, Ohio State University, Columbus, OH, USA; Department of Neuroscience, Ohio State University, Columbus, OH, USA; James Comprehensive Cancer Center and Solove Research Institute, Ohio State University, Columbus, OH, USA; Departments of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, USA. Electronic address: leah.pyter@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH